• Je něco špatně v tomto záznamu ?

Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status

A. Dolnikova, D. Kazantsev, M. Klanova, E. Pokorna, D. Sovilj, CD. Kelemen, L. Tuskova, E. Hoferkova, M. Mraz, K. Helman, N. Curik, K. Machova Polakova, L. Andera, M. Trneny, P. Klener

. 2024 ; 8 (13) : 3532-3543. [pub] 20240709

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013331

Venetoclax (VEN), a B-cell lymphoma 2 (BCL2) inhibitor, has a promising single-agent activity in mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and large BCLs, but remissions were generally short, which call for rational drug combinations. Using a panel of 21 lymphoma and leukemia cell lines and 28 primary samples, we demonstrated strong synergy between VEN and A1155463, a BCL-XL inhibitor. Immunoprecipitation experiments and studies on clones with knockout of expression or transgenic expression of BCL-XL confirmed its key role in mediating inherent and acquired VEN resistance. Of note, the VEN and A1155463 combination was synthetically lethal even in the cell lines with lack of expression of the proapoptotic BCL2L11/BIM and in the derived clones with genetic knockout of BCL2L11/BIM. This is clinically important because BCL2L11/BIM deletion, downregulation, or sequestration results in VEN resistance. Immunoprecipitation experiments further suggested that the proapoptotic effector BAX belongs to principal mediators of the VEN and A1155463 mode of action in the BIM-deficient cells. Lastly, the efficacy of the new proapoptotic combination was confirmed in vivo on a panel of 9 patient-derived lymphoma xenografts models including MCL (n = 3), B-ALL (n = 2), T-ALL (n = 1), and diffuse large BCL (n = 3). Because continuous inhibition of BCL-XL causes thrombocytopenia, we proposed and tested an interrupted 4 days on/3 days off treatment regimen, which retained the desired antitumor synergy with manageable platelet toxicity. The proposed VEN and A1155463 combination represents an innovative chemotherapy-free regimen with significant preclinical activity across diverse BCL2+ hematologic malignancies irrespective of the BCL2L11/BIM status.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013331
003      
CZ-PrNML
005      
20240905134334.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2024012906 $2 doi
035    __
$a (PubMed)38713893
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dolnikova, Alexandra $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000259826523
245    10
$a Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status / $c A. Dolnikova, D. Kazantsev, M. Klanova, E. Pokorna, D. Sovilj, CD. Kelemen, L. Tuskova, E. Hoferkova, M. Mraz, K. Helman, N. Curik, K. Machova Polakova, L. Andera, M. Trneny, P. Klener
520    9_
$a Venetoclax (VEN), a B-cell lymphoma 2 (BCL2) inhibitor, has a promising single-agent activity in mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and large BCLs, but remissions were generally short, which call for rational drug combinations. Using a panel of 21 lymphoma and leukemia cell lines and 28 primary samples, we demonstrated strong synergy between VEN and A1155463, a BCL-XL inhibitor. Immunoprecipitation experiments and studies on clones with knockout of expression or transgenic expression of BCL-XL confirmed its key role in mediating inherent and acquired VEN resistance. Of note, the VEN and A1155463 combination was synthetically lethal even in the cell lines with lack of expression of the proapoptotic BCL2L11/BIM and in the derived clones with genetic knockout of BCL2L11/BIM. This is clinically important because BCL2L11/BIM deletion, downregulation, or sequestration results in VEN resistance. Immunoprecipitation experiments further suggested that the proapoptotic effector BAX belongs to principal mediators of the VEN and A1155463 mode of action in the BIM-deficient cells. Lastly, the efficacy of the new proapoptotic combination was confirmed in vivo on a panel of 9 patient-derived lymphoma xenografts models including MCL (n = 3), B-ALL (n = 2), T-ALL (n = 1), and diffuse large BCL (n = 3). Because continuous inhibition of BCL-XL causes thrombocytopenia, we proposed and tested an interrupted 4 days on/3 days off treatment regimen, which retained the desired antitumor synergy with manageable platelet toxicity. The proposed VEN and A1155463 combination represents an innovative chemotherapy-free regimen with significant preclinical activity across diverse BCL2+ hematologic malignancies irrespective of the BCL2L11/BIM status.
650    12
$a sulfonamidy $x farmakologie $x terapeutické užití $7 D013449
650    _2
$a lidé $7 D006801
650    12
$a protein bcl-X $x metabolismus $x antagonisté a inhibitory $7 D051020
650    12
$a bicyklické sloučeniny heterocyklické $x farmakologie $x terapeutické užití $7 D019086
650    12
$a protein BCL2L11 $x metabolismus $x genetika $7 D000072224
650    12
$a chemorezistence $7 D019008
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a protoonkogenní proteiny c-bcl-2 $x metabolismus $x antagonisté a inhibitory $7 D019253
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a synergismus léků $7 D004357
650    _2
$a isochinoliny $7 D007546
650    _2
$a benzothiazoly $7 D052160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kazantsev, Dmitry $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000156608080
700    1_
$a Klanova, Magdalena $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Department of Medicine, Department of Hematology, Charles University General Hospital, Prague, Czech Republic
700    1_
$a Pokorna, Eva $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000307474623
700    1_
$a Sovilj, Dana $u Institute of Biotechnology Czech Academy of Sciences/Biotechnology and Biomedicine Centre of the Czech Academy of Sciences and Charles University, Vestec, Czech Republic $1 https://orcid.org/0000000287015912
700    1_
$a Kelemen, Cristina Daniela $u Institute of Biotechnology Czech Academy of Sciences/Biotechnology and Biomedicine Centre of the Czech Academy of Sciences and Charles University, Vestec, Czech Republic
700    1_
$a Tuskova, Liliana $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Department of Medicine, Department of Hematology, Charles University General Hospital, Prague, Czech Republic
700    1_
$a Hoferkova, Eva $u Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000271856119
700    1_
$a Mraz, Marek $u Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Helman, Karel $u Faculty of Informatics and Statistics, University of Economics, Prague, Czech Republic $1 https://orcid.org/0000000171418074 $7 xx0260953
700    1_
$a Curik, Nikola $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Machova Polakova, Katerina $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Andera, Ladislav $u Institute of Biotechnology Czech Academy of Sciences/Biotechnology and Biomedicine Centre of the Czech Academy of Sciences and Charles University, Vestec, Czech Republic $u Institute of Molecular Genetics CAS, Prague, Czech Republic
700    1_
$a Trneny, Marek $u First Department of Medicine, Department of Hematology, Charles University General Hospital, Prague, Czech Republic
700    1_
$a Klener, Pavel $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Department of Medicine, Department of Hematology, Charles University General Hospital, Prague, Czech Republic $1 https://orcid.org/0000000177869378 $7 xx0105452
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 8, č. 13 (2024), s. 3532-3543
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38713893 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134328 $b ABA008
999    __
$a ok $b bmc $g 2143255 $s 1225197
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 8 $c 13 $d 3532-3543 $e 20240709 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20240725
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace